Oncology Brands

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.

Prescription oncology medicine (everolimus) used to treat certain cancers and tuberous sclerosis complex, developed and marketed by Novartis AG.

Groundbreaking anti-VEGF biologic cancer therapy (bevacizumab) developed by Genentech and owned by Roche, FDA approved February 26, 2004, that reached peak global sales of $7.1 billion in 2019 and now faces biosimilar competition including Mvasi (Amgen) and multiple other approved alternatives.

Independent specialty pharmacy providing personalized patient care for oncology and rare disease treatments owned by McKesson Corporation.

Specialty pharmacy division of Cardinal Health, providing distribution and management services for high-cost, complex medications used in oncology, rheumatology, and other specialty therapeutic areas.

Groundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by Genentech and owned by Roche, FDA approved September 25, 1998, that transformed the treatment of HER2-positive breast cancer and now faces biosimilar competition from multiple approved alternatives.

Roche's HER2-targeted antibody-drug conjugate (ado-trastuzumab emtansine, T-DM1) developed by Genentech using ImmunoGen's DM1 cytotoxic technology, FDA approved February 22, 2013, for HER2-positive metastatic breast cancer and later for early-stage HER2-positive breast cancer following the KATHERINE trial.

Prescription immunotherapy medication for treating various cancers by activating the immune system, manufactured and marketed by Merck & Co.

Takeda's oral proteasome inhibitor (ixazomib citrate), FDA approved November 20, 2015, as the first and only oral proteasome inhibitor approved for multiple myeloma, used in combination with lenalidomide and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy, based on the TOURMALINE-MM1 Phase 3 trial.

Physician-led community oncology platform providing practice management, clinical support, and healthcare solutions to independent oncology practices owned by Cencora.

Roche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved June 8, 2012, that targets a different HER2 domain than Herceptin and is used in combination with Herceptin and chemotherapy for HER2-positive breast cancer in both metastatic and early-stage settings.

Roche's anti-CD20 chimeric monoclonal antibody (rituximab) co-developed by Genentech and IDEC Pharmaceuticals, FDA approved November 26, 1997, as the first monoclonal antibody approved for cancer treatment, now facing biosimilar competition from Truxima, Ruxience, and Riabni.

Roche's first-generation EGFR tyrosine kinase inhibitor (erlotinib) co-developed by Genentech and OSI Pharmaceuticals, FDA approved November 18, 2004, for EGFR-mutant non-small cell lung cancer and pancreatic cancer, with the branded product now discontinued as generic erlotinib is widely available.

Prescription oncology medication for treating chronic myeloid leukemia, owned by Novartis, facing generic competition after its US patent expired in January 2024, with nilotinib generics now available in the market.

Sanofi's taxane chemotherapy (docetaxel), FDA approved in 1996 for breast cancer and later for lung, prostate, gastric, and head and neck cancers, that generated $1.4 billion annually by 2004 before generic competition and became subject to major litigation over undisclosed risk of permanent hair loss.

Roche's oral fluoropyrimidine chemotherapy (capecitabine) developed by Genentech, FDA approved April 30, 1998, as the first oral chemotherapy for metastatic breast cancer and later for metastatic colorectal cancer, now available as generic capecitabine following patent expiration.